ArticleFrontiers in oncology2025
Diffuse gliomas: insights into clinical and histopathological features and survival rates from two centers in a middle-income country.
Article in Frontiers in oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed, 2 syntheses or guidelines pooled it.
- Glioma management and outcome in low-middle-income countries: a systematic review.Frontiers in oncology · 2026Pooled it
- High-grade gliomas where resources define survival: a systematic review and meta-analysis of outcomes, surgical access, and molecular diagnostic gaps in low- and middle-income countries.Frontiers in oncology · 2026Pooled it
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
19 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Gliomas are believed to arise from neuroglial stem cells and are histologically classified based on morphological similarities to normal neuroglial cells. This study aims to describe the clinical, histopathological, and demographic features of glioma patients treated in two reference centers in Colombia. Methods: This descriptive cross-sectional study included all patients with a histologically confirmed glioma treated at two institutions in Bogotá, Colombia, between January 2015 and December 2023. 272 patients with diffuse gliomas were included, and data were collected on sociodemographic characteristics, clinical presentation, histopathologic diagnosis, immunohistochemical markers, extent of resection, functionality, complications, and survival. Results: Amongst all cases, 36.00% were glioblastomas, 14.70% oligodendrogliomas, and 12.10% astrocytomas. 49.10% of patients were females, average age was 48.8 ± 21.0 years. While in the frontal lobe, most glioblastomas (38.95%) and oligodendrogliomas (47.50%) were found, astrocytomas were more frequent in the insula (27.27%). The average follow-up was 11.8 ± 16.0 months. Near-total resection was achieved in 40.10% of patients, followed by subtotal resection (37.00%), gross-total resection (11.45%), and intentional biopsy (11.45%). 31.25% of patients had new-onset motor deficits, and only 3% persisted after the 3-month follow-up. Overall survival was higher in females (males: 28.57% vs. females: 55.00%) (p = 0.0013). The 2-year overall survival for glioblastoma was 21%, 5-year for glioma, NOS 38%, for astrocytoma 15%, and 8-year for oligodendroglioma 5% (p < 0.0001). Conclusions: We present the largest study to date of diffuse glioma in Colombia's population. Clinical findings and overall survival trends are similar to those reported worldwide, however, further molecular analysis is needed for adequate diagnosis and classification.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.